Li Qiong, Yu Tao, Wang Fang, Liu Xin, Wang Zuolin
Department of Oral Implantology, School & Hospital of Stomatology, Tongji University, Shanghai Engineering Research Center of Tooth Restoration and Regeneration Shanghai 200072, China.
Department of Orthopedic Surgery, Tongji Hospital, Tongji University School of Medicine Shanghai 200065, China.
Am J Transl Res. 2020 Jun 15;12(6):2409-2424. eCollection 2020.
Mesenchymal stem cell (MSC)-based bone tissue engineering is a promising treatment option for maxillary sinus augmentation. Rapid vascularization is necessary to enhance the osteoinductive efficacy and prevent necrosis of the tissue-engineered bone. This study investigated whether the co-autotransplantation of endothelial progenitor cells (EPCs) could significantly enhance the osteogenic efficacy of MSCs and prevent necrosis of the tissue-engineered bone in a maxillary sinus augmentation model in dogs.
We evaluated the osteogenic activities of a clinically-used scaffold-deproteinized bovine bone (Bio-Oss) by examining cell adhesion and alkaline phosphatase (ALP) activity. , sinus augmentations were performed identically on both sides of dogs (n = 3 per group) using three treatment groups: (A) Bio-Oss with MSCs and EPCs; (B) Bio-Oss with MSCs; and (C) Bio-Oss with EPCs. The tissue implants were evaluated 24 weeks post-implantation.
, co-application of EPCs and MSCs on Bio-Oss significantly enhanced adhesion and ALP activity. , co-autotransplantation of MSCs and EPCs resulted in a significantly higher height, compressive strength, bone volume density, trabecular thickness, and trabecular number and a significantly lower trabecular separation compared with the other groups. The fluorescent test showed co-autotransplantation caused a significantly higher mineral apposition rate than the other groups. Histomorphometric analysis showed co-application resulted in the highest rate of new bone formation. Newly formed bone was frequently in the center of the implants with EPCs and MSCs, but not the other implants.
Co-autotransplantation of EPCs and MSCs significantly enhanced the osteogenic efficacy, suggesting promising potential for sinus augmentation.
基于间充质干细胞（MSC）的骨组织工程是上颌窦提升的一种有前景的治疗选择。快速血管化对于提高骨诱导效力和防止组织工程骨坏死是必要的。本研究调查了内皮祖细胞（EPC）的共同自体移植是否能在犬上颌窦提升模型中显著提高MSC的成骨效力并防止组织工程骨坏死。
我们通过检测细胞黏附及碱性磷酸酶（ALP）活性来评估临床使用的脱蛋白牛骨支架（Bio-Oss）的成骨活性。在犬的双侧（每组n = 3）进行相同的窦提升手术，使用三个治疗组：（A）Bio-Oss联合MSC和EPC；（B）Bio-Oss联合MSC；（C）Bio-Oss联合EPC。植入后24周对组织植入物进行评估。
EPC和MSC在Bio-Oss上的联合应用显著增强了黏附及ALP活性。与其他组相比，MSC和EPC的共同自体移植导致更高的高度、抗压强度、骨体积密度、小梁厚度和小梁数量以及更低的小梁间距。荧光测试显示共同自体移植导致的矿物质沉积率显著高于其他组。组织形态计量学分析显示联合应用导致最高的新骨形成率。新形成的骨常位于含EPC和MSC的植入物中心，而其他植入物则不然。
EPC和MSC的共同自体移植显著提高了成骨效力，提示在上颌窦提升方面具有广阔的应用前景。
